Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 multicenter study to assess the safety and effectiveness of brentuximab
vedotin and bendamustine, when given together, in patients with Hodgkin Lymphoma or
Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial
treatment(s). Patients will be accrued at Columbia University Medical Center (CUMC) and at
two subsites in Canada.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Columbia University Owen A. O'Connor
Collaborators:
British Columbia Cancer Agency Princess Margaret Hospital, Canada